Fistulising Crohn's disease: MMPs gone awry

Gut

Volumn 53, Issue 5, 2004, Pages 622-624

  Schuppan, D ^a   Freitag, T ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; CHEMOKINE; GELATINASE A; IMMUNOSUPPRESSIVE AGENT; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; PROTEIN INHIBITOR;

CELL MIGRATION; CROHN DISEASE; ENDOTHELIUM CELL; FIBROGENESIS; FISTULA; HUMAN; NOTE; PRIORITY JOURNAL; PROTEIN STRUCTURE;

CROHN DISEASE; HUMANS; INTESTINAL FISTULA; MATRIX METALLOPROTEINASES;

EID: 2342433268     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.034207     Document Type: Note

References (29)

1. Sandborn WJ, Fazio VW, Feagan BG, et al. AGA technical review on perianol Crohn's disease. Gastroenterology 2003;125:1508-30.
2. Matthes H, Herbst H, Schuppan D, et al. Cellular localization of procollagen gene transcripts in inflammatory bowel dieseases. Gastroenterology 1992;102:431-42.
3. Pender SL, Tickle SP, Docherty AJ, et al. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997;158:1582-90.
4. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a toil of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3:207-14.
5. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
6. Dumin JA, Dickeson SK, Stricker TP. Procollagenase-1 (matrix metalloproteinase-1) binds the alpha(2)beta(1) integrin upon release from keratinocytes migrating on type I collagen. J Biol Chem 2001;276:29368-74.
7. Yu Q, Stomenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999;13:35-48.
8. Schuppan D, Ruehl M, Somasundaram R, et al. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001;21:351-72.
9. Ruehl M, Somasundaram R, Farndale R, et al. Pro-matrix-metalloproteinase- 2 (MMP-2) is bound to liver collagens via collagenous consensus mitives and released from extracellular matrix stores by activation. (abstract). Gastroenterology 2002;122(suppl 1):A653.
10. Günther U, Schuppan D, Matthes H, et al. Fibrogenesis and fibrolysis in collagenaus colitis: patterns of procollagen type I and IV, matrix-metalloproteinase-1, and TIMP-1 gene expression. Am J Pathol, 155:493-503.
11. Heuschkel RB, MacDonald TT, Manteleone G, et al. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut 2000;47:57-62.
12. von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000;47:63-73.
13. Kirkegaard T, Hansen A, Bruun E, et al. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut 2004;53:701-9.
14. Swiderski RE, Dencoff JE, Floerchinger CS, et al. Differential expression of extracellular matrix remodeling genes in a murine model of bleomycin-induced pulmonary fibrosis. Am J Pathol 1998;152:821-8.
15. Ammarguellat FZ, Gannon PO, Amiri F, et al. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rots: role of ET(A) receptors. Hypertension 2002;39:679-84.
16. Fritsch C, Simon-Assmann P, Kedinger M, et al. Cytokines modulate fibroblast phenotype and epithelial-stroma interactions in rat intestine. Gastroenterology 1997;112:826-38.
17. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001;21:373-84.
18. Baker AH, Edwards DR, Murphy G. Metallaproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719-27.
19. Buckley CD. Why does chronic inflammatory joint disease persist? Clin Med 2003;3:361-6.
20. Mercapide J, Lopez De Cicco R, Castresana JS, et al. Stramelysin-1/matrix metalloproteinase-3 (MMP-3) expression accounts for invasive properties of human astrocytoma cell lines. Int J Cancer 2003;106:676-82.
21. Salmela MT, MacDonald TT, Black D, et al. Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridisation. Gut 2002;51:540-7.
22. Liu Z, Klominek J. Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors. Thorax 2003;58:198-203.
23. Lee HS, Miau LH, Chen CH, et al. Differential role of p38 in IL-1alpha induction of MMP-9 and MMP-13 in an established liver myofibroblast cell line. J Biomed Sci 2003;10:757-65.
24. Di Sebastiano P, di Mala FF, Artese L, et al. Beneficial effects of Batimastot (BB-94), a matrix metalloproteinase inhibitor, in rot experimental colitis. Digestion 2001;63:234-9.
25. Lauer-Fields JL, Sritharan T, Stack MS, et al. Selective hydrolysis of triple-helical substrates by matrix metalloproteinase-2 and -9. J Biol Chem 2003;278:18140-5.
26. Pender SL, Salmela MT, Manteleone G, et al. Ligation of alpha4β1 integrin on human intestinal mucosal mesenchymal cells selectively up-regulates membrane type-1 matrix metalloproteinase and confers a migratory phenotype. Am J Pathol 2000;157:1955-62.
27. Chen CC, Chen N, Lau LF. The angiogenic factors Cyr61 and connective tissue growth factor induce adhesive signaling in primary human skin fibroblasts. J Biol Chem 2001;276:10443-52.
28. Rolli M, Fronsvea E, Pilch J, et al. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:9482-7.
29. Tucker GC. Alpha v integrin inhibitors and cancer therapy. Curr Opin Invest Drugs 2003;4:722-31.